55 /100
HIGH RISK
Score updated May 30, 2026

OSTX — OS Therapies Incorporated Dilution Risk Tracker

Track OSTX dilution risk with DilutionWatch's stock tracker. DilutionScore™ measures dilution risk across 5 factors — lower scores indicate higher risk of share dilution.

⚠️ Not financial advice. Do your own research before making any investment decisions.

🔔 Track OSTX — Get alerts when the score changes →

📊 Score Breakdown

📋 Offering Ability
60
💰 Cash Runway
65
📊 Float Risk
10
⚠️ Warrant Exposure
15
🔄Convertible Debt

🌦️ Dilution Forecast

🌥️
Advisory
Moderate dilution signals present
38%
🔄 Reverse Split 40%
• 50-day avg $1.57 approaching $1 threshold
• 8 months cash with weak price
📉 Score Deterioration 40%
• Score rose 36 points recently (worsening)
💰 Capital Raise 33%
• Under 12 months cash (8mo)
• Active ATM program with $4M remaining capacity
🔔 Track OSTX — Get forecast alerts →

💹 Market Data

Market Cap$95.31M
Shares Outstanding44.54M
Float36.21M
Cash$917.6K
Debt$1.34M
Short InterestN/A

🏛 Institutional Holdings

QoQ: ↑ 13.6% shares (2025Q4 vs prior)
25 institutional holders · 1.78M shares
#1 VANGUARD GROUP INC 540.4K shares
#2 CM Management, LLC 400.0K shares
#3 GEODE CAPITAL MANAGEMENT, LLC 246.0K shares
+ 17 more holders Sign up free to view →

📉 Short Interest

Short Interest1.32M
Days to Cover2.2
% of Float3.6%
FINRA data as of May 15, 2026

📁 Recent SEC Activity

xbrl XBRL WARRANT Mar 31, 2026
xbrl XBRL CONVERTIBLE Dec 31, 2024
424B5 ATM Apr 02, 2026
8-K 8K EVENT Apr 02, 2026
8-K 8K EVENT Mar 31, 2026
Full SEC filing analysis available with free account

📰 Recent News

No recent news
Track OSTX Dilution Risk in Real-Time
Get instant alerts when SEC filings impact dilution risk. Free tier available.
Start Tracking OSTX — Free
Real-time SEC alerts DilutionScore™ tracking No credit card required
🔬 More Research for OSTX
📊 OSTX FDA Catalyst Timeline & Biotech Grade — BiotechSigns 📡 OSTX Signal Convergence & Dark Pool Activity — StonkWhisper 📄 OSTX Dilution Risk Analysis — Full In-Depth Report

Part of the Guerilla Finance research network. Cross-reference multiple data sources for better due diligence.